A new combination therapy that pairs a radiopharmaceutical (177Lu-DOTATATE) with a DNA-repair blocker (olaparib) has been deemed feasible and tolerable for neuroendocrine cancer patients. The combined therapy works by preventing ...
May 22, 2025
0
23
A new treatment approach significantly improves survival rates for patients with aggressive, inherited breast cancers, according to Cambridge researchers.
May 13, 2025
0
52
The combination of the PARP inhibitor olaparib and the PD-1 inhibitor pembrolizumab showed initial antitumor activity with no new safety signals in a molecularly matched, tumor-agnostic trial, particularly in patients with ...
Apr 28, 2025
0
14
Ovarian cancer has seen a significant shift in its treatment paradigm with the introduction of poly (ADP-ribose) polymerase (PARP) inhibitors, which are now standard in the maintenance setting following first-line chemotherapy.
Jan 23, 2025
0
20
Published in Clinical Cancer Research, results of a VHIO-led study underscore the potential of the RAD51 biomarker in tailoring treatment strategies in patients with early breast cancer.
Jan 13, 2025
0
38
Patients with high-risk, BRCA-positive breast cancer who received olaparib (Lynparza) after standard treatment continued to have better survival outcomes than those who received placebo after a median follow-up of 6.1 years, ...
Dec 11, 2024
0
24
Scientists have worked out a way of predicting how long a prostate cancer patient will continue to respond to the PARP inhibitor drug olaparib, according to new research published in the journal Cancer Cell.
Nov 21, 2024
0
25
A combination therapy improved progression-free survival in patients with metastatic castration-resistant prostate cancer with distinct genetic mutations compared to either therapy alone or sequentially, according to results ...
Sep 9, 2024
0
27
Led by investigators of the Vall d'Hebron Institute of Oncology's (VHIO) Experimental Therapeutics Group, in collaboration with VHIO's Hereditary Cancer Genetics Group and the Medical Oncology Department at the Vall d'Hebron ...
Sep 3, 2024
0
35
The anti-cancer drug olaparib may be effective in treating biochemically recurrent prostate cancer without accompanying hormone therapy for men who have mutations in genes such as BRCA2, according to results of a Phase II ...
Aug 22, 2024
0
38
